Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) [Phase 1]

View source ↗

Summary

This completed Phase 1 pediatric study assessed the pharmacokinetics, safety, and tolerability of Mirabegron oral suspension in children aged 3 to less than 12 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity
• Overactive Bladder

Drugs mentioned

• Myrbetriq (mirabegron)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Overactive Bladder, Neurogenic Detrusor Overactivity | Phase 1 | Status: COMPLETED